Enbrel TV Ad Highlighting “Breakthrough Therapy” Draws FDA Warning Letter
Executive Summary
A television commercial for Amgen's Enbrel (etanercept) describing the TNF inhibitor as a "breakthrough" psoriasis therapy has drawn an FDA warning letter
You may also be interested in...
Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says
Amgen sees the advent of Part D as an opportunity for Enbrel to capture some of the Medicare TNF inhibitor rheumatoid arthritis market share currently held byJohnson & Johnson's Remicade
Enbrel To Cut Into Remicade’s Medicare Monopoly Via Part D, Amgen Says
Amgen sees the advent of Part D as an opportunity for Enbrel to capture some of the Medicare TNF inhibitor rheumatoid arthritis market share currently held byJohnson & Johnson's Remicade
J&J Remicade Sales Aid Cited By FDA For “Misleading” Efficacy Claims
A Remicade sales aid contains unsubstantiated effectiveness claims and omits risk information, the Center for Drug Evaluation & Research's advertising division says in a Feb. 11 "untitled" letter to Johnson & Johnson's Centocor division